Filed with ASX · · 4 pages · English
Mayne Pharma Group Ltd. has announced that the FDA confirmed the fulfillment of post-marketing study requirements for IMVEXXY, a vaginal estrogen product, indicating no association with endometrial cancer risk. Completion of this requirement removes all outstanding FDA obligations for IMVEXXY, reinforcing its favorable benefit-risk profile.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
ASX Announcement FDA CONFIRMS FULFILMENT OF IMVEXXY® POST-MARKETING STUDY REQUIREMENTS Key Points • The US Food and Drug Administration (FDA) has confirmed the Company has fulfilled its post-approval obligations by completing the post-marketing requirement (PMR) safety study for IMVEXXY®...
Mayne Pharma Group Ltd. on 6ix
